An observational study in Prehepatic Portal Hypertension, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Hypertension, Portal with a site in China — 38 open to participants now, 40 under way, none of them phase 3. Hypertension, Portal · China.
Among the 106 studies in Hypertension, Portal with a site in China, this one is the 39th largest by enrollment of the 42 observational ones that give a count, is one of 10 that started in 2025, is one of 42 observational ones, and was the 104th registered.
376 studies on the registry are indexed under Hypertension, Portal; 115 are open to participants now.
Browse Hypertension, Portal studies →38 of the 106 studies in Hypertension, Portal with a site in China are open now. Recruiting first, the newest first:
Air Force Military Medical University, China · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 69 Hypertension, Portal studies recruiting now, 33 (48%) set no upper age limit and 13 (19%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 4 · Phase 4 8
First in 2006; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 150 across 135 observational studies indexed under Hypertension, Portal.
Median enrollment 100 across the 64 interventional studies, 258 across the 42 observational. Of the 28 that completed or were terminated, 4 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 106 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 104 studies on the registry; 70 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 1 study filed under Hypertension, Portal — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertension, Portal with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06122753West China HospitalPreemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis | 2026-12 |
| NCT07080697Zhejiang UniversityA Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension | 2027-02-28 |
| NCT07462091Northern Jiangsu People's HospitalVagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection | 2027-03-31 |
| NCT07350070Tongji HospitalTACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension | 2027-06-30 |
| NCT07116096Shanxi Provincial People's HospitalEffect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis | 2027-08-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 106 studies in Hypertension, Portal with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Portal hypertension caused by prehepatic vascular obstruction, such as portal vein thrombosis or portal vein tumor thrombosis, represents a unique hemodynamic condition in which conventional hepatic venous pressure gradient (HVPG) measurement may not accurately reflect portal venous pressure. Endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement provides a direct approach for assessing portal hemodynamics.
This retrospective observational study included patients with cirrhosis and esophagogastric varices complicated by portal vein thrombosis or portal vein tumor thrombosis. All patients underwent abdominal computed tomography to confirm the presence of portal vein obstruction, liver stiffness measurement by ultrasound elastography, HVPG measurement, and EUS-PPG measurement. The study aims to evaluate the relationship between EUS-PPG and HVPG and to explore the associations between portal pressure measurements and clinical characteristics, including underlying liver disease etiology, liver function grade, sex, gastrointestinal bleeding, and hepatic encephalopathy.
This study included patients with liver cirrhosis complicated by prehepatic portal hypertension due to portal venous obstruction. All patients had esophagogastric varices and underwent abdominal computed tomography, ultrasound elastography, hepatic venous pressure gradient measurement, and endoscopic ultrasound-guided portal pressure gradient measurement. The study evaluated the relationship between portal pressure measurements and clinical characteristics, including liver disease etiology, liver function grade, gastrointestinal bleeding, and hepatic encephalopathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥18 years; Confirmed diagnosis of cirrhosis complicated by portal venous obstructionbased on clinical, laboratory, and imaging findings; Written ;
Exclusion Criteria:
Severe coagulopathy, defined as an (INR) >1.5; Severe thrombocytopenia, defined as a count \<30 × 10\^9/L; Severe systemic comorbidities, including active sepsis, decompensated heart failure, or severe ; Psychiatric or cognitive disorders that preclude cooperation with study procedures; Refusal to undergo hepatic venous pressure gradient (HVPG) or endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement;
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Correlation Between EUS-Guided Portal Pressure Gradient and Hepatic Venous Pressure Gradient
The correlation between portal pressure gradient measured by endoscopic ultrasound-guided direct portal pressure measurement (EUS-PPG) and hepatic venous pressure gradient (HVPG) will be assessed using paired measurements obtained during the same procedural session. Both EUS-PPG and HVPG are measured in mmHg. The strength of the correlation will be quantified using a correlation coefficient.
Time frame: Periprocedural
Difference Between Distal-to-Obstruction and Proximal-to-Obstruction EUS-Guided Portal Pressure Gradients
The difference between distal-to-obstruction portal pressure gradient (dis-Obs PPG) and proximal-to-obstruction portal pressure gradient (pro-Obs PPG), measured by endoscopic ultrasound-guided direct portal pressure measurement, will be assessed using paired measurements obtained during the same procedural session. Both pressure gradients are measured in mmHg.
Time frame: Periprocedural
Difference Between Distal-to-Obstruction EUS-Guided Portal Pressure Gradient and Hepatic Venous Pressure Gradient
The difference between distal-to-obstruction portal pressure gradient (dis-Obs PPG), measured by endoscopic ultrasound-guided direct portal pressure measurement, and hepatic venous pressure gradient (HVPG), measured by standard hepatic venous catheterization, will be assessed using paired measurements obtained during the same procedural session. Both pressure gradients are measured in mmHg.
Time frame: Periprocedural
Difference in Distal-to-Obstruction EUS-Guided Portal Pressure Gradient Between Patients With and Without Variceal Bleeding
Distal-to-obstruction portal pressure gradient (dis-Obs PPG), measured by endoscopic ultrasound-guided direct portal pressure measurement and expressed in mmHg, will be compared between patients with and without variceal bleeding related to portal hypertension.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Jun 2026, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, Zhejiang University, School of Medicine →